Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

about

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

P2860

Q38223419-BD334C60-B52D-4F5B-B0A1-CF4CD153342B Q38400073-ACC61852-06DA-422A-BE13-745A1EF87E06

P2860

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

Item

http://www.wikidata.org/entity/Q37031896

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

@en

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

@nl

type

Item

label

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

@en

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

@nl

prefLabel

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

@en

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

@nl

P1476

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

@en

P2093

Alex Graham

http://www.w3.org/2001/XMLSchema#string

Joe Conner

http://www.w3.org/2001/XMLSchema#string

Lynne Braidwood

http://www.w3.org/2001/XMLSchema#string

Sheila V Graham

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Oncolytic herpes simplex virus vectors for cancer virotherapy

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

P304

57-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OV.S52601

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27512658

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

chemotherapy

P932

4918355

http://www.w3.org/2001/XMLSchema#string

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

about

P2860

P2860

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932